Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company has closed a growth capital funding round of $168 million.

Before its two most recent rounds, Caris snagged $150 million in debt financing in October 2018 from Sixth Street, which also contributed an additional $75 million in debt financing to the 2020 round.

Caris Life Sciences announced plans to go public, testing a technology initial public offering market that’s been frozen over for most of the year.. The Irving-based AI diagnostic company said ...

Caris Life Sciences was founded in 2008 in Irving. TBJ file image. By Sydney Asher – Staff Writer, Dallas Business Journal. May 30, 2025. Updated May 30, 2025 5:32pm CDT. Preview this article 1 min.